S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65
S&P 500   4,486.46
DOW   35,258.61
QQQ   372.65

Dyne Therapeutics Stock Forecast, Price & News

-0.70 (-4.70 %)
(As of 10/18/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume89,176 shs
Average Volume305,890 shs
Market Capitalization$727.12 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DYN News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Dyne Therapeutics logo

About Dyne Therapeutics

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$7.53 per share


Net Income
$-59.44 million




Market Cap
$727.12 million
Next Earnings Date
11/4/2021 (Estimated)
Not Optionable


Overall MarketRank

1.45 out of 5 stars

Medical Sector

1069th out of 1,361 stocks

Pharmaceutical Preparations Industry

512th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Dyne Therapeutics (NASDAQ:DYN) Frequently Asked Questions

Is Dyne Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Dyne Therapeutics stock.
View analyst ratings for Dyne Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Dyne Therapeutics?

Wall Street analysts have given Dyne Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Dyne Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Dyne Therapeutics?

Dyne Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 2,090,000 shares, an increase of 26.7% from the September 15th total of 1,650,000 shares. Based on an average daily trading volume, of 240,500 shares, the short-interest ratio is currently 8.7 days. Approximately 7.6% of the company's shares are short sold.
View Dyne Therapeutics' Short Interest

When is Dyne Therapeutics' next earnings date?

Dyne Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Dyne Therapeutics

How were Dyne Therapeutics' earnings last quarter?

Dyne Therapeutics, Inc. (NASDAQ:DYN) released its earnings results on Thursday, August, 5th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.03.
View Dyne Therapeutics' earnings history

How has Dyne Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Dyne Therapeutics' stock was trading at $12.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DYN shares have increased by 10.7% and is now trading at $14.18.
View which stocks have been most impacted by COVID-19

Who are Dyne Therapeutics' key executives?

Dyne Therapeutics' management team includes the following people:
  • Mr. Joshua T. Brumm, CEO, Pres & Director (Age 43, Pay $789.44k)
  • Dr. Romesh Subramanian Ph.D., Co-Founder & Advisor (Age 55, Pay $565.17k)
  • Ms. Susanna Gatti High M.B.A., Chief Operating Officer (Age 53, Pay $409.31k) (LinkedIn Profile)
  • Mr. Gene Kim, VP of Fin. (Age 44)
  • Mr. Richard Scalzo, VP of Accounting & Admin. and Treasurer (Age 35)
  • Dr. Oxana Beskrovnaya Ph.D., Chief Scientific Officer (Age 60)
  • Ms. Amy Reilly, VP of Corp. Communications & Investor Relations (Age 47)
  • Dr. Thomas-Christian Mix M.D., Sr. VP of Clinical Devel. (Age 54)
  • Ms. Debra Feldman, VP & Head of Regulatory Affairs (Age 50)
  • Mr. Daniel Wilson, VP & Head of Intellectual Property (Age 49)

When did Dyne Therapeutics IPO?

(DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO.

What is Dyne Therapeutics' stock symbol?

Dyne Therapeutics trades on the NASDAQ under the ticker symbol "DYN."

How do I buy shares of Dyne Therapeutics?

Shares of DYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dyne Therapeutics' stock price today?

One share of DYN stock can currently be purchased for approximately $14.18.

How much money does Dyne Therapeutics make?

Dyne Therapeutics has a market capitalization of $727.12 million. The company earns $-59.44 million in net income (profit) each year or ($4.13) on an earnings per share basis.

How many employees does Dyne Therapeutics have?

Dyne Therapeutics employs 47 workers across the globe.

What is Dyne Therapeutics' official website?

The official website for Dyne Therapeutics is www.dyne-tx.com.

How can I contact Dyne Therapeutics?

The company can be reached via email at [email protected].

This page was last updated on 10/19/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.